Vistin Pharma ASA reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported sales was NOK 95.05 million compared to NOK 77.8 million a year ago. Revenue was NOK 110.93 million compared to NOK 78.12 million a year ago. Net income was NOK 16.93 million compared to NOK 7.16 million a year ago. Basic earnings per share from continuing operations was NOK 0.38 compared to NOK 0.16 a year ago. Diluted earnings per share from continuing operations was NOK 0.38 compared to NOK 0.16 a year ago.
For the full year, sales was NOK 287.68 million compared to NOK 275.81 million a year ago. Revenue was NOK 304.85 million compared to NOK 278.62 million a year ago. Net loss was NOK 4.69 million compared to net income of NOK 24.96 million a year ago. Basic loss per share from continuing operations was NOK 0.11 compared to basic earnings per share from continuing operations of NOK 0.56 a year ago. Diluted loss per share from continuing operations was NOK 0.11 compared to diluted earnings per share from continuing operations of NOK 0.56 a year ago.